Mircera

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
07-12-2023
Karakteristik produk Karakteristik produk (SPC)
07-12-2023

Bahan aktif:

Methoxy polyethylene glycol-epoetin beta

Tersedia dari:

Roche Registration GmbH

Kode ATC:

B03XA03

INN (Nama Internasional):

methoxy polyethylene glycol-epoetin beta

Kelompok Terapi:

Antianemic preparations

Area terapi:

Anemia; Kidney Failure, Chronic

Indikasi Terapi:

Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1).Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1).

Ringkasan produk:

Revision: 29

Status otorisasi:

Authorised

Tanggal Otorisasi:

2007-07-20

Selebaran informasi

                                53
B. PACKAGE LEAFLET
54
PACKAGE LEAFLET: INFORMATION FOR THE USER
MIRCERA
30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
120 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
150 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
200 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
250 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
360 MICROGRAMS/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
methoxy polyethylene glycol-epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What MIRCERA is and what it is used for
2.
What you need to know before you use MIRCERA
3.
How to use MIRCERA
4.
Possible side effects
5.
How to store MIRCERA
6.
Contents of the pack and other information
1.
WHAT MIRCERA IS AND WHAT IT IS USED FOR
This medicine is prescribed to you because you have anaemia caused by
your chronic kidney disease
and associated with typical symptoms, such as tiredness, weakness and
shortness of breath. This
means that you have too few red blood cells and your haemoglobin level
is too low (your body’s
tissues might not receive enough oxygen).
MIRCERA is indicated to treat only the symptomatic an
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
MIRCERA 30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 120 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 150 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 200 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 250 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
MIRCERA 360 MICROGRAMS/0.6 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
MIRCERA 30 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 30 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 100 micrograms/ml
MIRCERA 40 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 40 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 133 micrograms/ml.
MIRCERA 50 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 50 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 167 micrograms/ml.
MIRCERA 60 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 60 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 200 micrograms/ml.
MIRCERA 75 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
One pre-filled syringe contains 75 micrograms of methoxy polyethylene
glycol-epoetin beta* at a
concentration of 250 micrograms/ml
MIRCERA 100 MICROGRAMS/0.3 ML SOLUTION FOR INJECTION IN PRE-FILLED
SYRINGE
O
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 07-12-2023
Karakteristik produk Karakteristik produk Bulgar 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 11-08-2023
Selebaran informasi Selebaran informasi Spanyol 07-12-2023
Karakteristik produk Karakteristik produk Spanyol 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 11-08-2023
Selebaran informasi Selebaran informasi Cheska 07-12-2023
Karakteristik produk Karakteristik produk Cheska 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 11-08-2023
Selebaran informasi Selebaran informasi Dansk 07-12-2023
Karakteristik produk Karakteristik produk Dansk 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 11-08-2023
Selebaran informasi Selebaran informasi Jerman 07-12-2023
Karakteristik produk Karakteristik produk Jerman 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 11-08-2023
Selebaran informasi Selebaran informasi Esti 07-12-2023
Karakteristik produk Karakteristik produk Esti 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 11-08-2023
Selebaran informasi Selebaran informasi Yunani 07-12-2023
Karakteristik produk Karakteristik produk Yunani 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 11-08-2023
Selebaran informasi Selebaran informasi Prancis 07-12-2023
Karakteristik produk Karakteristik produk Prancis 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 11-08-2023
Selebaran informasi Selebaran informasi Italia 07-12-2023
Karakteristik produk Karakteristik produk Italia 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 11-08-2023
Selebaran informasi Selebaran informasi Latvi 07-12-2023
Karakteristik produk Karakteristik produk Latvi 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 11-08-2023
Selebaran informasi Selebaran informasi Lituavi 07-12-2023
Karakteristik produk Karakteristik produk Lituavi 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 11-08-2023
Selebaran informasi Selebaran informasi Hungaria 07-12-2023
Karakteristik produk Karakteristik produk Hungaria 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 11-08-2023
Selebaran informasi Selebaran informasi Malta 07-12-2023
Karakteristik produk Karakteristik produk Malta 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 11-08-2023
Selebaran informasi Selebaran informasi Belanda 07-12-2023
Karakteristik produk Karakteristik produk Belanda 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 11-08-2023
Selebaran informasi Selebaran informasi Polski 07-12-2023
Karakteristik produk Karakteristik produk Polski 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 11-08-2023
Selebaran informasi Selebaran informasi Portugis 07-12-2023
Karakteristik produk Karakteristik produk Portugis 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 11-08-2023
Selebaran informasi Selebaran informasi Rumania 07-12-2023
Karakteristik produk Karakteristik produk Rumania 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 11-08-2023
Selebaran informasi Selebaran informasi Slovak 07-12-2023
Karakteristik produk Karakteristik produk Slovak 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 11-08-2023
Selebaran informasi Selebaran informasi Sloven 07-12-2023
Karakteristik produk Karakteristik produk Sloven 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 11-08-2023
Selebaran informasi Selebaran informasi Suomi 07-12-2023
Karakteristik produk Karakteristik produk Suomi 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 11-08-2023
Selebaran informasi Selebaran informasi Swedia 07-12-2023
Karakteristik produk Karakteristik produk Swedia 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 11-08-2023
Selebaran informasi Selebaran informasi Norwegia 07-12-2023
Karakteristik produk Karakteristik produk Norwegia 07-12-2023
Selebaran informasi Selebaran informasi Islandia 07-12-2023
Karakteristik produk Karakteristik produk Islandia 07-12-2023
Selebaran informasi Selebaran informasi Kroasia 07-12-2023
Karakteristik produk Karakteristik produk Kroasia 07-12-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 11-08-2023

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen